Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  

27 November 2020

The ground-breaking work of MIA's Co-Medical Director Professor Richard Scolyer, one of the world’s leading cancer pathologists, has today been recognised with NSW’s highest accolade for cancer research at the 2020 NSW Premier’s Awards for Outstanding Cancer Research.  

The Outstanding Cancer Researcher of the Year Award is awarded to an individual researcher who has made an active, outstanding, sustained contribution to any field of cancer research in NSW; has a record of substantive and noteworthy publications; and has supported, developed and mentored cancer researchers.

Professor Scolyer was named Outstanding Cancer Researcher of the Year at this year’s awards, which were hosted online due to the impact of COVID-19, for his pioneering melanoma research which has made a worldwide difference to the assessment, management and survival of people with cancer.   

Chief Cancer Officer and CEO of the Cancer Institute NSW, Professor David Currow, said the body of work amassed by Professor Scolyer throughout his career has made a real difference to how clinicians and researchers think about melanoma.  

“Over the past 20 years, Professor Scolyer has made an extraordinary and significant contribution to the field of cancer medicine through pathology. He is the most published scientist in the world in the field of melanoma pathology, he leads a world-renowned translational research laboratory at the University of Sydney, and he is the co-lead of the world’s largest melanoma treatment facility, the Melanoma Institute of Australia,” Professor Currow said.   

“Sadly, melanoma is Australia’s national cancer, with a person diagnosed in NSW, on average, every six hours. This year, around 16,000 Australians will be diagnosed and around 1400 are expected to die from the disease.  

“Ten years ago, people diagnosed with advanced melanoma had their life expectancy measured in months. Now, Australian people with melanoma have a range of increasingly personalised treatment options. There are people alive today, in NSW and around the world, thanks to work done by Professor Scolyer and his amazing teams,” he said. 

Premier Gladys Berejiklian congratulated Professor Scolyer on his remarkable career. 

“I want to thank and congratulate Professor Scolyer for his ground-breaking research into melanoma, a cancer that affects the lives of so many Australians,” Ms Berejiklian said. 

Commenting on his award win, Prof Scolyer said,

“We have an amazing team of people doing world leading melanoma research and it’s a huge honour to be leading that team and to be recognised in this way. Pathologists have a unique role to play in translational research and are key members of multidisciplinary teams which are conducting research at a high level. Pathologists are the bridge between the patient and what goes on in the research laboratory, bringing a unique perspective in order to facilitate research.”

For two decades, Prof Scolyer has been at the forefront of virtually all major advances in melanoma which have revolutionised management worldwide and resulted in vast improvements in survival of melanoma patients.

“Every cancer patient ultimately has their cancer diagnosed by a pathologist; what we see down the microscope and include in our reports determines how a patient is managed. The thing about research is that there is an opportunity not only to benefit a single patient, but to make a difference to many thousands of patients that will be affected down the track. This is what makes research so important,” said Prof Scolyer.

The NSW Government, through the Cancer Institute NSW, has invested more than $240 million in cancer research since 2011. 

For a full list of winners of the 2020 NSW Premier’s Awards for Outstanding Cancer Research, visit: Cancer Premiers Research Awards 

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration
23 Oct 2018

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.

Monthly dose of immunotherapy allows flexibility for patients undergoing treatment
11 Oct 2018

Monthly dose of immunotherapy allows flexibility for patients undergoing treatment

A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.

Australia's best minds in melanoma research converge on Melbourne
08 Oct 2018

Australia's best minds in melanoma research converge on Melbourne

The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.

Nobel Prize for novel cancer therapies
04 Oct 2018

Nobel Prize for novel cancer therapies

The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.

World Health Organisation launches 4th edition of Classification of Skin Tumours
31 Aug 2018

World Health Organisation launches 4th edition of Classification of Skin Tumours

The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.

Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
31 Aug 2018

Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal

Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.

Support PBS listing for pembrolizumab
23 Aug 2018

Support PBS listing for pembrolizumab

Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.

World Congress on Cancers of the Skin 2018
17 Aug 2018

World Congress on Cancers of the Skin 2018

The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.

Melanoma Institute Australia welcomes new CEO Matthew Browne
09 Aug 2018

Melanoma Institute Australia welcomes new CEO Matthew Browne

Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).

Melanoma in Practice: Nurse Conference
26 Jul 2018

Melanoma in Practice: Nurse Conference

It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’. 

Reducing the risk of melanoma in young adults
19 Jul 2018

Reducing the risk of melanoma in young adults

A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.

Melanoma Institute Australia launches free e-learning education portal
20 Jun 2018

Melanoma Institute Australia launches free e-learning education portal

Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.

David Day and a lifetime of missed moments
08 Jun 2018

David Day and a lifetime of missed moments

When David lost his life last year, he was 33, with three daughters under six.

Australian melanoma experts share latest breakthroughs with world's best oncologists
06 Jun 2018

Australian melanoma experts share latest breakthroughs with world's best oncologists

ASCO 2018 brings together the world's best in oncology from around the world. 

ASCO 2018 – the important role of clinical trials
06 Jun 2018

ASCO 2018 – the important role of clinical trials

Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.

MIA Scoops Awards at the International Academy of Pathology
04 Jun 2018

MIA Scoops Awards at the International Academy of Pathology

Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology. 

Updated Clinical Guidelines for Melanoma
25 May 2018

Updated Clinical Guidelines for Melanoma

Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.

Melanoma and Marital Status: A Study
11 May 2018

Melanoma and Marital Status: A Study

An American study has discovered a link between early detection and marital status in melanoma diagnosis. 

A weekend in Paris talking all things pathology...
02 May 2018

A weekend in Paris talking all things pathology...

An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.

Our own 'Australian Story'
30 Apr 2018

Our own 'Australian Story'

Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.